Peptide Comparison
Angiotensin (1-7)vsThymosin Beta-4
The heart-friendly peptide that balances your blood pressure and protects your cardiovascular system
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Angiotensin (1-7)
0.5-1 mcg/kg–5-10 mcg/kg mcg
Thymosin Beta-4
2–5 mg
Frequency
Angiotensin (1-7)
Once daily
Thymosin Beta-4
Twice weekly
Administration
Angiotensin (1-7)
As directed by healthcare provider
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Angiotensin (1-7)
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
Angiotensin (1-7)
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Angiotensin (1-7)
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Heart Health & Protection
Blood Pressure Balance
Anti-Inflammatory Support
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Angiotensin (1-7)
Molecular Formula
C41H62N12O11
Molecular Weight
899.02 g/mol
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
25016-41-7
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
Angiotensin (1-7)
Cardiovascular health and heart protection
Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Blood pressure management and hypertension
Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from heart-related conditions
Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory support
Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Angiotensin (1-7)
Common
- Hypotension (Low Blood Pressure)
- Dizziness or Lightheadedness
- Injection Site Reactions
- Headache
Serious
- Hyperkalemia (High Potassium)
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Angiotensin (1-7)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.
Contraindications
- xSevere hypotension or uncontrolled low blood pressure
- xAcute myocardial infarction in early stages
- xConcurrent use with certain ACE inhibitors without medical supervision
- xPregnancy and breastfeeding (insufficient safety data)
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Angiotensin (1-7) if...
- Cardiovascular health and heart protection
- Blood pressure management and hypertension
- Recovery from heart-related conditions
- Anti-inflammatory support
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation